scholarly journals LaSota Strain Expressing The Rabies Virus Glycoprotein (rL-RVG) Suppresses Gastric Cancer by Inhibiting the Alpha 7 Nicotinic Acetylcholine Receptor (α7 nAChR)/Phosphoinositide 3-Kinase (PI3K)/AKT Pathway

2019 ◽  
Vol 25 ◽  
pp. 5482-5492
Author(s):  
Xuefeng Bu ◽  
Chaoyun Yin ◽  
Xuanfeng Zhang ◽  
Anwei Zhang ◽  
Xiaomei Shao ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Acetylcholine Receptor ◽  
Nicotinic Acetylcholine Receptor ◽  
Rabies Virus ◽  
Akt Pathway ◽  
Nicotinic Acetylcholine ◽  
Virus Glycoprotein ◽  
Α7 Nachr ◽  
Alpha 7 ◽  
Phosphoinositide 3 Kinase

scholarly journals Alpha-7 nicotinic acetylcholine receptor agonists in intracerebral hemorrhage: an evaluation of the current evidence for a novel therapeutic agent

2013 ◽  
Vol 34 (5) ◽  
pp. E10 ◽  
Author(s):  
Eric S. Sussman ◽  
Christopher P. Kellner ◽  
Michael M. McDowell ◽  
Samuel S. Bruce ◽  
Simon G. Heuts ◽  
...  
Keyword(s):  
Intracerebral Hemorrhage ◽  
Acetylcholine Receptor ◽  
Nicotinic Acetylcholine Receptor ◽  
Therapeutic Agent ◽  
Current Evidence ◽  
Secondary Injury ◽  
Nicotinic Acetylcholine ◽  
Α7 Nachr ◽  
Alpha 7 ◽  
Novel Therapeutic

Intracerebral hemorrhage (ICH) is the most deadly and least treatable subtype of stroke, and at the present time there are no evidence-based therapeutic interventions for patients with this disease. Secondary injury mechanisms are known to cause substantial rates of morbidity and mortality following ICH, and the inflammatory cascade is a major contributor to this post-ICH secondary injury. The alpha-7 nicotinic acetylcholine receptor (α7-nAChR) agonists have a well-established antiinflammatory effect and have been shown to attenuate perihematomal edema volume and to improve functional outcome in experimental ICH. The authors evaluate the current evidence for the use of an α7-nAChR agonist as a novel therapeutic agent in patients with ICH.

scholarly journals The Association Between Alpha-7 Nicotinic Acetylcholine Receptor and Microglial Polarization in Spinal Cord Injury: Nicotine as an Alternative Therapy for Neuroinflammation

2020 ◽  
Author(s):  
Abolfazl Badripour ◽  
Kamyar Moradi ◽  
Zahra Ebrahim Soltani ◽  
Sayna Bagheri ◽  
Pasha Reza Shams Azar ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Acetylcholine Receptor ◽  
Nicotinic Acetylcholine Receptor ◽  
Treated Group ◽  
Male Rats ◽  
Nicotinic Acetylcholine ◽  
Α7 Nachr ◽  
Cord Injury ◽  
Alpha 7

Abstract Background: Nicotine is an agonist of alpha-7 nicotinic acetylcholine receptor (α7 nAChR). The association between the expression of α7 nAChR and neuroinflammation has been extensively reported. Herein, we assessed the efficacy of Nicotine in the management of spinal cord injury (SCI) complications and mediating mechanisms.Methods: In this study, 64 male rats were randomly allocated to 7 SCI and a sham-operated groups. SCI was induced through an aneurysmal clip at the T9/T10 level. The group list consists of a non-treated group as the control, four Nicotine-treated groups receiving 0.5, 1, 1.5, and 3 mg/kg of the drug, a Methyllycaconitine (MLA, 1.5 mg/kg)-treated group, a group of rodents receiving MLA plus the most effective dosage of Nicotine, and a sham one. Locomotion and mechanical allodynia were assessed during 28 days using the Basso, Beattie, Bresnahan (BBB) and von Frey methods, respectively. In the end, spinal cord samples were taken to assess cavity formation, the expression levels of M1 and M2 macrophages, pro-inflammatory and anti-inflammatory factors, as well as α7 nAChR and NF-κB gene levels.Results: Repeated measures analysis revealed significant effect of time-treatment interaction on locomotion [F (42, 336) = 120.2, p < 0.001] and mechanical sensitivity [F (35, 280) = 45.47, p < 0.001]. Behavioral response to Nicotine was dose-dependent, and 1 mg/kg of this reagent was the most efficient dosage. H&E staining represented lesser histopathological disruptions in Nicotine-treated animals. SCI increased the M1/M2 ratio (p < 0.001) via shifting macrophages polarization towards M1 subset and 1 mg/kg of Nicotine could attenuate this ratio (p < 0.001) through reversing the shift. Meanwhile, Nicotine administration resulted in a significant elevation of α7 nAChR and a reduction of NF-κB genes. Finally, in the Nicotine group, there were declines in the levels pro-inflammatory biomarkers, including TNF-α, IL-1β, and IL-6, while IL-10 was found higher than the control group (p values < 0.05). MLA-treated groups showed almost none of the aforementioned alterations. Conclusion: Single-dose therapy with Nicotine could improve locomotor and sensory complications of SCI. Nicotine possible mechanism of action is through increasing the α7 nAChR level, which alleviates neuro-inflammation by changing microglial phenotyping.

scholarly journals Cognitive Enhancers in Schizophrenia: A Systematic Review and Meta-Analysis of Alpha-7 Nicotinic Acetylcholine Receptor Agonists for Cognitive Deficits and Negative Symptoms

2021 ◽  
Vol 12 ◽  
Author(s):  
María Recio-Barbero ◽  
Rafael Segarra ◽  
Arantzazu Zabala ◽  
Eduardo González-Fraile ◽  
Ana González-Pinto ◽  
...  
Keyword(s):  
Acetylcholine Receptor ◽  
Nicotinic Acetylcholine Receptor ◽  
Negative Symptoms ◽  
Antipsychotic Treatment ◽  
Controlled Trials ◽  
Nicotinic Acetylcholine ◽  
Cognitive Domains ◽  
Receptor Agonists ◽  
Α7 Nachr ◽  
Alpha 7

Background: Schizophrenia is a severe and enduring disease and is one of the leading causes of disability worldwide. Cognitive impairment is a core clinical symptom that plays a crucial role in functional outcomes and prognosis, thus making it a relevant treatment target. The aim of this study was to assess the efficacy of alpha-7 nicotinic acetylcholine receptor agonists (α7 nAChR) as adjunctive treatment to enhance cognition and ameliorate negative symptoms in patients with schizophrenia.Methods: A search strategy was developed for MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials up to May 2019. We included randomized controlled trials (RCTs) that compared antipsychotic treatment plus α7 nAChR agonists with antipsychotic treatment plus placebo and determined their effects on the main cognitive domains proposed by the MATRICS initiative and on negative symptoms. Two authors independently reviewed study eligibility and data extraction and assessed the risk of bias of the studies included. According to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework, we used a random-effects model and assessed the quality of the evidence.Results: Thirteen studies were included in the quantitative analysis. No differences were found in any of the cognitive domains assessed in four RCTs (n = 414). In contrast, nine RCTs (n = 978) presented a small effect in support of α7 nAChR agonists for negative symptoms [standardized mean difference −0.28, 95% CI (−0.56 to −0.00); P = 0.05], even though the confidence to support this evidence is low according to the GRADE system.Conclusions: Current evidence is too weak to consider α7 nAChR agonists as an effective add-on treatment to antipsychotics to enhance cognition and negative symptoms.

Alpha 7-nicotinic acetylcholine receptor mediates the sensitivity of gastric cancer cells to 5-fluorouracil

Tumor Biology ◽  
2015 ◽  
Vol 36 (12) ◽  
pp. 9537-9544 ◽  
Author(s):  
Wei-Yu Chen ◽  
Chien-Yu Huang ◽  
Wan-Li Cheng ◽  
Chin-Sheng Hung ◽  
Ming-Te Huang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Cells ◽  
Acetylcholine Receptor ◽  
Nicotinic Acetylcholine Receptor ◽  
Gastric Cancer Cells ◽  
Nicotinic Acetylcholine ◽  
Alpha 7
Sign in / Sign up

Export Citation Format

Share Document